Oklahoma 10th Circuit: Weighs 340B Nondiscrimination Act Appeal

• Oklahoma appealed a preliminary injunction blocking its 340B Nondiscrimination Act, which aims to expand patient access to discounted drugs.
• Pharmaceutical companies AbbVie, AstraZeneca, and Novartis sued, arguing the state law violated federal preemption and constituted unconstitutional takings.
• U.S. District Judge Patrick Wyrick granted the preliminary injunction on October 31, 2025, halting the state law's implementation.
• The 10th Circuit hearing involved judges questioning the law's potential burden on manufacturers and its impact on drug delivery efficiency versus demand.
• Oklahoma asserts its law merely clarifies drug delivery methods, arguing Congress did not prohibit state regulation in this area of the 340B Drug Pricing Program.

The core legal question before the 10th Circuit centers on whether state legislation can dictate the delivery mechanisms for drugs under the federal 340B program without conflicting with federal law or imposing undue burdens on pharmaceutical manufacturers.

The 10th Circuit Court of Appeals recently heard arguments in Denver regarding Oklahoma's bid to reinstate its 340B Nondiscrimination Act, a state law designed to broaden patient access to discounted medications under the federal 340B Drug Pricing Program. Oklahoma is appealing a preliminary injunction that currently blocks the law, which pharmaceutical giants AbbVie LLC, AstraZeneca, and Novartis Pharmaceuticals Corporation successfully challenged in district court. The outcome of this Oklahoma 10th Circuit 340B Nondiscrimination Act appeal carries significant implications for the future of state-level regulation concerning 340B drug delivery and the compliance landscape for pharmaceutical manufacturers and healthcare providers across the nation.

Oklahoma's state attorney, Garry Gaskins, argued before the appellate panel that Congress did not specify how 340B drugs should be delivered, contending that the manufacturers' lawsuit seeks to interpret this legislative silence as a prohibition against state-level delivery regulations. This legal battle highlights a fundamental tension between state efforts to ensure broader drug access for vulnerable populations and pharmaceutical companies' claims of undue burden and federal preemption. The 10th Circuit's decision will be closely watched by stakeholders in the pharmaceutical and healthcare sectors, as it could set a precedent for how states can legislate around federal drug pricing schemes.

The federal 340B Drug Pricing Program, established by the Veterans Health Care Act in 1992, allows eligible healthcare providers to purchase outpatient drugs at significantly discounted prices. These 'covered entities' — which include black lung clinics, rural referral centers, and hospitals serving low-income patients — then bill insurers at full price, using the generated revenue to support their operations and patient care. U.S. District Judge Patrick Wyrick, who initially enjoined Oklahoma's law, famously described the 340B Program as 'the most important drug pricing scheme virtually no one has heard of,' noting its primary design was for the benefit of healthcare providers rather than directly for patients.

Oklahoma's 340B Nondiscrimination Act was enacted last year with the explicit goal of preventing pharmaceutical manufacturers from restricting the delivery options available to patients receiving these discounted medications. The state asserts that this expansion of access is crucial, particularly for rural healthcare infrastructure. Oklahoma's appeal brief highlighted that approximately three-quarters of its rural hospitals rely on the 340B program to remain operational. The University of Oklahoma Medical Center, for instance, reportedly provides medication to patients in diverse locations ranging from Orlando to Las Vegas and Puerto Rico, underscoring the broad reach and importance of ensuring efficient 340B drug access regardless of the pickup location.

The pharmaceutical companies — AbbVie LLC, AstraZeneca, and Novartis Pharmaceuticals Corporation — each initiated separate lawsuits against Oklahoma, asserting that the state's new law violated the federal preemption clause and constituted unconstitutional takings. Their core contention was that the Oklahoma 340B drug delivery law compelled them to provide more discounted products in more locations than previously required, thereby imposing an undue burden. Following a hearing in the Novartis case, U.S. District Judge Patrick Wyrick, a Donald Trump appointee, issued a preliminary injunction on October 31, 2025, effectively blocking the state's 340B Nondiscrimination Act. This single opinion provided relief across all three separate lawsuits.

Judge Wyrick's decision prompted Oklahoma's immediate appeal to the 10th Circuit, setting the stage for the current appellate review. The core legal question before the 10th Circuit centers on whether state legislation can dictate the delivery mechanisms for drugs under the federal 340B program without conflicting with federal law or imposing undue burdens on pharmaceutical manufacturers. This 340B Drug Pricing Program litigation underscores the complex interplay between federal regulatory frameworks and state-level initiatives aimed at healthcare access.

During the 10th Circuit hearing, which featured dual arguments presented back-to-back, judges probed the implications of Oklahoma's law. Senior U.S. Circuit Judge David Ebel, a Ronald Reagan appointee, questioned Oklahoma's state attorney Garry Gaskins on the potential burdens the law might place on pharmaceutical businesses. Judge Ebel inquired whether the law would necessitate increased production, asking, 'Does that mean you have to crank up production?' and 'Would this require someone to build another factory?' He also pressed on the interpretation of 'unlimited amounts' versus a manufacturer's actual capacity.

In response, Gaskins clarified that under existing federal law, drug manufacturers participating in the 340B program are already obligated to provide as many discounted medications as covered medical providers request, stating, 'The drug manufacturer is supposed to honor that order at the 340B price.' He added, 'I don’t know what happens if they can’t meet demand.' U.S. Circuit Judge Carolyn McHugh, a Barack Obama appointee, further questioned whether expanding drug availability necessarily translated to increased demand. Judge McHugh observed that the issue primarily concerned the logistics of drug distribution, noting, 'As I understand it, there is not an expansion of who is qualified to get these drugs. All that is changing is the efficiency of how the drugs get to patients.' Jessica Ellsworth, representing Novartis, reiterated that discounted drugs were already accessible to patients, implying the state law was an unnecessary intervention.

Lawyers and compliance officers in the pharmaceutical and healthcare sectors should closely monitor the 10th Circuit's decision on Oklahoma's 340B Nondiscrimination Act, as it could establish a significant precedent for state-level regulation of 340B drug delivery and impact compliance obligations for manufacturers and covered entities within the 10th Circuit and potentially nationwide.

Source: Original reporting via CN